FrancophonIA/ELRC3.0 huggingface dataset:
English: Should subsequent surgery be intended in a dog previously treated with the veterinary medicinal product, a minimum of a 7 day dosing interval must be observed before administering another dose.
Croatian: U slučaju namjere izvršenja uzastopne operacije na psu koji je prethodno liječen ovim veterinarsko-medicinskim proizvodom, potreban je protek od minimalno 7 dana prije primjene naredne doze.
English: Withdrawing the solution from the vial Attaching the applicator tip (see Figure 3):
Croatian: Postavljanje vrha aplikatora (vidi Prikaz 3):
English: Therefore, treated dogs of more than 20 kg body weight have to be kept at the hospital for 48 hours post-application.
Croatian: Prema tome, liječeni psi preko 20 kg tjelesne težine moraju se zadržati na klinici 48 nakon primjene.
English: • rare (more than 1 but less than 10 animals in 10,000 animals)
Croatian: • rijetke (više od 1 ali manje od 10 životinja u 10.000 životinja)
English: Store the broached vial with the adaptor in an upright position.
Croatian: Čuvajte otvorenu bočicu s adapterom u uspravnom položaju.
English: Eesti
Croatian: Estonija
English: Elanco Santé Animale 24 Boulevard Vital Bouhot 92200 Neuilly sur Seine Paris Tel. : +33/(0)1 55 49 35 29 France
Croatian: Elanco Santé Animale 24 Boulevard Vital Bouhot 92200 Neuilly sur Seine Paris
English: Do no re-use the applicator tip.
Croatian: Nemojte ponovo upotrebljavati vrh aplikatora.
English: This product should only be administered by a veterinary surgeon.
Croatian: Ovaj proizvod smije primijeniti samo veterinar.
English: Република България
Croatian: Češka republika
English: PACKAGE LEAFLET Recuvyra 50 mg/ml transdermal solution for dogs
Croatian: UPUTA O VMP ZA: Recuvyra 50 mg/ml transdermalna otopina za pse
English: Terminal half-life (hrs)
Croatian: Poluvrijeme života (sati)
English: EXP: MM/YYYY Once broached, use within 30 days.
Croatian: Nakon što se otvori, upotrijebite u roku od 30 dana.
English: • uncommon (more than 1 but less than 10 animals in 1,000 animals)
Croatian: • manje česte (više od 1 ali manje od 10 životinja u 1000 životinja)
English: Ireland (Ireland)
Croatian: Irska
English: Dogs of more than 20 kg bodyweight should remain in the hospital for a minimum of 48 hours following application.
Croatian: Psi s više od 20 kg tjelesne težine moraju ostati u klinici najmanje 48 sati nakon primjene.
English: ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
Croatian: Prikaz 4. Primjena proizvoda
English: Slovenija (Slovenia)
Croatian: Slovenija
English: Rua Galileu Galilei, Nº2 Piso 7 Fracção A/D 1500 - 392 LISBOA
Croatian: Torre Ocidente Rua Galileu Galilei, Nº2 Piso 7
English: Polska (Poland)
Croatian: Poljska
English: 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Croatian: 6.6 Posebne mjere opreza prilikom odlaganja neupotrebljenog veterinarsko-medicinskog proizvoda ili otpadnih materijala dobivenih primjenom tih proizvoda Bilo koji neupotrebljeni veterinarsko-medicinski proizvod ili otpadni materijali dobiveni primjenom tih veterinarsko-medicinskih proizvoda trebaju se odlagati u skladu s lokalnim propisima.
English: Do not use the veterinary medicinal product in lactating or pregnant bitches or breeding animals (see section 4.7).
Croatian: Više peroralne doze mogu dovesti do anestetičkih efekata i kardiopulmonarne depresije.Ne primjenjivati veterinarsko-medicinski proizvod na gravidnim kujama ili dojiljama (vidi dio 4.7).
English: METHOD AND ROUTE(S) OF ADMINISTRATION For transdermal use.
Croatian: NAČIN I PUT(EVI) PRIMJENE
English: Recuvyra is a solution designed to be applied to the skin between the shoulder blades of your dog (see picture) only by a veterinarian using a specially designed single use applicator, which does not involve any needles.
Croatian: primjenjuje ju samo veterinar pomoću posebno dizajniranog aplikatora za jednokratnu upotrebu koji ne sadrži igle.
English: Dosing device:
Croatian: Uređaj za doziranje:
English: Attaching the Applicator Tip
Croatian: Prikaz 3. Postavljanje vrha aplikatora
English: Tel.: +45 45 26 60 60 Denmark
Croatian: Tel.: + 45 45 26 60 60 Danska
English: WITHDRAWAL PERIOD Not applicable.
Croatian: Nije primjenjivo.
English: Tel.: + 45 45 26 6060 Denmark
Croatian: Tel.: + 45 45 26 6060 Danska
English: Spain
Croatian: Finska
English: Manufacturer for batch release:
Croatian: Nositelj odobrenja za proizvodnju odgovoran za puštanje serije u promet:
English: Store the vial together with the Summary of Product Characteristics (SPC).
Croatian: Čuvajte bočicu zajedno sa Sažetkom opisa svojstava.
English: B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE
Croatian: OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE U PROMET
English: Store vial upright with the adaptor attached.
Croatian: Čuvajte bočicu u uspravnom položaju s postavljenim adapterom.
English: Ελλάδα
Croatian: Lot {broj}
English: A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET
English: Eli Lilly Regional Operations GmbH Elanco Animal Health
Croatian: Hrvatska Eli Lilly Regional Operations GmbH
English: Germany
Croatian: Grčka
English: Tel.: +45 45 26 6060 Denmark
Croatian: +45 45 26 6060 Danska
English: Tel.: + 45 45 26 60 60 Denmark
Croatian: +45 45 26 60 60 Danska
English: What Senstend is and what it is used for
Croatian: Što je Senstend i za što se koristi
English: Store below 25 °C.
Croatian: Čuvati ispod 25 °C.
English: EU/1/19/1387/001 EU/1/19/1387/002
Croatian: EU/1/19/1387/002
English: Frequency of the adverse reactions is defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Croatian: Učestalost nuspojava definirana je kao: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).
English: This is particularly important if you are taking the following medicines which may interact with Senstend:
Croatian: To je osobito važno ako uzimate sljedeće lijekove koji mogu reagirati s lijekom Senstend:
English: • medicines reducing your stomach acid (cimetidine)
Croatian: • lijekove koji vam smanjuju želučanu kiselinu (cimetidin).
English: What Senstend looks like and contents of the pack
Croatian: Kako Senstend izgleda i sadržaj pakiranja
English: • medicines for high blood pressure and to regulate your heart rhythm (so-called beta blockers)
Croatian: • lijekove protiv visokog krvnog tlaka i za regulaciju srčanog ritma (takozvani beta blokatori)
English: They are very unlikely to happen if it is used as instructed:
Croatian: Vrlo je mala vjerojatnost da će se pojaviti postupite li prema uputama:
English: Other medicines and Senstend
Croatian: Drugi lijekovi i Senstend
English: However, there may be some exposure in female partners of men treated with Senstend.
Croatian: Međutim, može doći do određene izloženosti kod partnerica muškaraca kod kojih je primijenjen Senstend.
English: Senstend is a combination of two medicines: lidocaine and prilocaine.
Croatian: Senstend je kombinacija dvaju lijekova: lidokaina i prilokaina.
English: Senstend has no or negligible influence on the ability to drive and use machines.
Croatian: Senstend ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: There is limited data on the efficacy and safety of Senstend in patients 65 years and over.
Croatian: Podaci o djelotvornosti i sigurnosti lijeka Senstend u pacijenata u dobi od 65 godina i više su ograničeni.
English: What Senstend is and what it is used for What you need to know before you use Senstend How to use Senstend
Croatian: Što je Senstend i za što se koristi Što morate znati prije nego počnete primjenjivati Senstend Kako primjenjivati Senstend
English: Therefore, both partners may feel slight numbness for a short while and should take care not to injure themselves, particularly during sexual activity.
Croatian: Posljedica toga je da bi oba partnera mogla osjetiti kratkotrajno blago utrnuće i trebaju paziti da se ne bi ozlijedili, pogotovo tijekom spolne aktivnosti.
English: The potential for reduction of sperm motility following the clinical use of the medicinal product can not be excluded; therefore it is not possible to state whether Senstend would prevent pregnancy.
Croatian: Potencijal za smanjenje pokretljivosti spermija nakon kliničke primjene lijeka ne može se isključiti; stoga nije moguće ustvrditi bi li Senstend spriječio trudnoću.
English: Pharmacotherapeutic group: Anaesthetics, amides, ATC code: N01BB20
Croatian: Farmakoterapijska skupina: Anestetici, amidi, ATK oznaka: N01BB20
English: The efficacy of Senstend was demonstrated in two multi-centre, multinational, randomised, double-blind, placebo controlled studies, both followed by an open-label phase.
Croatian: Djelotvornost lijeka Senstend dokazana je u dvije multicentrične, multinacionalne, randomizirane, dvostruko slijepe, placebom kontrolirane studije, obje naknadno praćene otvorenom fazom.
English: However this study did not reproduce the circumstances of clinical use, as the concentration of Senstend in direct contact with the sperm would be many fold lower.
Croatian: Međutim, ta studija nije reproducirala okolnosti kliničke primjene, budući da bi tada koncentracija lijeka Senstend u izravnom kontaktu sa spermom bila višestruko niža.
English: If you use Senstend with condoms, you may be more likely to be unable to develop or maintain an erection.
Croatian: Koristite li Senstend s kondomom, veća je vjerojatnost da nećete postići ili zadržati erekciju.
English: Human exposure from Senstend is 20-30 fold less than the minimum dose that did not result in tumours and 200 fold less than the minimum dose that did result in tumours.
Croatian: Izloženost lijeku Senstend u ljudi je 20-30 puta manja od najmanje doze koja nije dovela do razvoja tumora i 200 puta je manja od najmanje doze koja je dovela do razvoja tumora.
English: Adjusted mean change scores (Senstend vs. placebo) at Month 3 were 8.2 vs. 2.2 for the ejaculatory control score, 7.2 vs. 1.9 for the sexual satisfaction score, and 3.7 vs. 1.1 for the distress score.
Croatian: Prilagođene srednje vrijednosti promjene rezultata (Senstend naspram placebo) u 3. mjesecu bile su 8,2 naspram 2,2 kod bodovanja kontrole ejakulacije, 7,2 naspram 1,9 za bodovanje spolnog zadovoljstva i 3,7 naspram 1,1 za bodovanje tjeskobe.
English: Care should be taken not to allow Senstend to come in contact with the eye, as it may cause eye irritation.
Croatian: Potrebno je paziti da Senstend ne dođe u doticaj s očima budući da može izazvati nadraženost oka.
English: Senstend should not come into contact with a damaged ear drum.
Croatian: Senstend ne smije doći u doticaj s oštećenim bubnjićem.
English: A study in rats showed that Senstend caused a reduction in sperm motility.
Croatian: Ispitivanja na štakorima pokazala su da je Senstend izazvao smanjenje pokretljivosti spermija.
English: Senstend is not recommended for use whilst your partner is pregnant unless you use a male condom, as listed above, to prevent exposure of the unborn child.
Croatian: Ne preporučuje se primjena lijeka Senstend dok je vaša partnerica trudna, osim ako ne koristite muški kondom kako je gore navedeno, kako biste smanjili izloženost nerođenog djeteta.
English: 66.2% of Senstend-treated subjects and 18.8% of placebo-treated subjects achieved a mean IELT > 2 minutes.
Croatian: 66,2 % ispitanika liječenih lijekom Senstend i 18,8 % liječenih placebom postiglo je srednju vrijednost IELT > 2 minute.
English: The European Medicines Agency has waived the obligation to submit the results of studies with Senstend in all subsets of the paediatric population in primary premature ejaculation (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove (EMA) izuzela je obvezu podnošenja rezultata ispitivanja lijeka Senstend u svim podskupinama pedijatrijske populacije za primarnu preuranjenu ejakulaciju (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: The terminal elimination half-life of lidocaine from the plasma following intravenous administration is approximately 65 - 150 minutes and the systemic clearance is 10 - 20 mL/min/kg.
Croatian: Terminalno poluvrijeme eliminacije lidokaina iz plazme nakon intravenske primjene je oko 65 - 150 minuta, a sistemski klirens je 10 - 20 mL/min/kg.
English: During the 3 months of the double-blind treatment phase, the geometric mean IELT increased from 0.58 to 3.17 minutes in the Senstend group and from 0.56 to 0.94 minutes in the placebo group.
Croatian: Tijekom 3 mjeseca dvostruko slijepe faze liječenja, geometrijska e srednja vrijednost IELT-a povećala se s 0,58 na 3,17 minuta u skupini koja je koristila Senstend te s 0,56 na 0,94 minute u placebo skupini.
English: The clinically significant increases in IELT were paralleled by significant differences in the IPE scores (p < 0.0001).
Croatian: Klinički značajno povećanje IELT bilo je usporedno sa značajnim razlikama u IPE rezultatima (p < 0,0001).
English: This leaflet was last revised in {MM/YYYY}
Croatian: Ova uputa je zadnji puta revidirana u {MM/GGGG} Drugi izvori informacija
English: • loss of feeling in the mouth
Croatian: • gubitak osjeta u ustima
English: Any barrier contraceptives (e.g. male or female condom), which are made from polyurethane-based material cannot be guaranteed to protect against disease or pregnancy when you are also using Senstend.
Croatian: Sva mehanička sredstva za kontracepciju (kao što su muški ili ženski prezervativi) izrađena od poliuretanskih materijala ne mogu jamčiti sigurnost od prenosivih bolesti ili trudnoće kad se koriste uz Senstend.
English: Senstend is a colourless to light yellow cutaneous spray, solution in an aluminium spray container with metering valve.
Croatian: Senstend bezbojan je do svijetlo žuti sprej za kožu, otopina u aluminijskom spremniku spreja, s odmjernim ventilom.
English: What you need to know before you use Senstend Do not use Senstend
Croatian: Što morate znati prije nego počnete primjenjivati Senstend
English: Senstend is not approved for use by women.
Croatian: Senstend nije odobren za primjenu u žena.
English: Also contains: norflurane
Croatian: POPIS POMOĆNIH TVARI Također sadržava: norfluran
English: Plasma levels of these metabolites detected after administration of Senstend in clinical trials were low in both male and female subjects, even after doses of it many times in excess of the clinical dose were applied.
Croatian: Razine tih metabolita u plazmi utvrđenih nakon primjene lijeka Senstend pri kliničkim ispitivanjima bile su niske i u muških i u ženskih ispitanika, čak i kada su primjenjivane doze višestruko veće od kliničke doze.
English: The prilocaine metabolite o-toluidine has genotoxic potential in vitro.
Croatian: Metabolit prilokaina o-toluidin ima genotoksični potencijal in vitro.
English: 85.2% of subjects in the Senstend group achieved a mean IELT of > 1 minute over the course of 3 months of treatment with it, whereas 46.4% of the placebo subjects had a mean IELT of > 1 minute.
Croatian: 85,2 % ispitanika u skupini liječenoj lijekom Senstend postiglo je srednju vrijednost IELT od > 1 minute tijekom 3 mjeseca liječenja, dok je 46,4 % onih ispitanika koji su bili u placebo skupini imalo srednji IELT > 1 minute.
English: Talk to your doctor or pharmacist before using Senstend - if you, or your sexual partner, have been diagnosed with a genetic disease or other condition affecting your red blood cells (glucose-6-phosphate deficiency, anaemia or methaemoglobinaemia); - if you have a history of medicine sensitivities, especially if you are not certain which medicine causes sensitivity; - if you suffer from severe liver problems.
Croatian: Obratite se svom liječniku ili ljekarniku prije nego primijenite Senstend - ako vi ili vaša seksualna partnerica imate dijagnozu genetske bolesti ili drugog stanja koje ima utjecaja na crvene krvne stanice (nedostatak glukoza-6-fosfata, anemija ili methemoglobinemija), - ako ste nekada imali osjetljivosti na lijekove, posebno ako niste sigurni koji lijek je uzrok preosjetljivosti, - patite li od teških problema s jetrom.
English: Senstend may reduce the possibility of pregnancy, but is not a reliable contraceptive.
Croatian: Senstend može smanjiti vjerojatnost začeća, ali nije pouzdan kontraceptiv.
English: The risk of additional systemic toxicity should be considered when large doses of Senstend are applied to patients already using other local anaesthetics or structurally related medicinal products, e.g. class I anti-arrhythmics such as mexiletine.
Croatian: Potrebno je razmotriti mogućnost dodatnog rizika od sistemske toksičnosti kad se velike doze lijeka Senstend koriste u pacijenata koji već koriste druge lokalne anestetike ili strukturalno srodne lijekove npr. antiaritmike skupine
English: Senstend may also come into contact with other mucous membranes such as your, or your partner's, mouth, nose and throat, causing them to feel slightly numb for a short while.
Croatian: Senstend također može doći u doticaj s drugim sluznicama kao što su usta, nos ili grlo vas ili vaše partnerice, što će dovesti do osjeta blage utrnulosti na kraće vrijeme.
English: • discomfort or itching in the vulva and vagina
Croatian: • nelagoda ili svrbež u vulvi i vagini
English: In an in vitro study of rats Senstend has shown a reduction in sperm motility when 22.5 mg lidocaine and 7.5 mg prilocaine (i.e. the amount in 1 human dose) was in direct contact with rat sperm.
Croatian: Jedna in vitro studija lijeka Senstend na štakorima pokazala je smanjenje pokretljivosti spermija kad je 22,5 mg lidokaina i 7,5 mg prilokaina (tj. količina u 1 ljudskoj dozi) došlo u izravan kontakt sa spermom štakora.
English: Lidocaine and prilocaine are excreted in human milk, but at therapeutic doses of Senstend no effects on the breastfed newborns/infants are anticipated due to active substance transfer from the male patient to his female partner.
Croatian: Lidokain i prilokain izlučuju se majčino mlijeko, ali u terapijskim dozama lijeka Senstend ne očekuje se učinak na dojenu novorođenčad/dojenčad s obzirom na prijenos djelatne tvari od muškog pacijenta na njegovu partnericu.
English: The plasma levels of lidocaine and prilocaine in male and female subjects were below the level associated with toxicity (5,000 ng/ml).
Croatian: Razine lidokaina i prilokaina u plazmi u muških i ženskih ispitanika bile su ispod razine koja se povezuje s toksičnosti (5000 ng/mL).
English: In vitro interaction studies with topical antifungal (clotrimazole, econazole, imidazole, nystatin, miconazole, ketoconazole), antibacterial (clindamycin, metronidazole) and antiviral medicinal products (acyclovir), showed no effect on antimicrobial activity.
Croatian: In vitro studije interakcija s topikalnim antimikoticima (klotrimazol, ekonazol, imidazol, nistatin, mikonazol, ketokonazol), antibakterijskim (klindamicin, metronidazol) i antivirusnim lijekovima (aciklovir) nisu pokazale učinak na antimikrobnu aktivnost.
English: The recommended dose of Senstend is 3 sprays (3 sprays = 1 dose) on the head of the penis before sexual intercourse.
Croatian: Preporučena doza lijeka Senstend je 3 potiska (3 potiska = 1 doza) na glavić penisa prije spolnog odnosa.
English: Senstend sprayed onto mucous membranes of the patient or their partner, such as the mouth, nose and throat, or transferred onto female genitalia or anal lining, could be absorbed and temporary local numbness/anaesthesia is likely to result.
Croatian: Kad je Senstend nanesen na sluznice pacijenta ili partnerice, kao što su usta, nos i grlo, ili prenesen na genitalije žene ili analno područje, može biti apsorbiran i vjerojatna posljedica je privremena lokalna otupljenost/anestezija.
English: • Sulphonamides (also called sulpha medicines) e.g. sulfamethoxazole - an antibiotic used to treat urinary infections, and sulfasalazine - used to treat Crohn's disease, ulcerative colitis and rheumatoid arthritis
Croatian: • Sulfonamidi (koji se nazivaju sulfa lijekovi) npr. sulfametoksazol - antibiotik koji se koristi za liječenje infekcije mokraćnog sustava i sulfasalazin - koristi se za liječenje Crohnove bolesti, ulceroznog kolitisa i reumatoidnog artritisa
English: Female volunteers receiving repeated doses directly to the cervix and vagina of up to five times the recommended dose for the male partner, had maximum plasma levels of lidocaine which were less than 8% of toxic levels, and prilocaine which were less than 1% of toxic levels.
Croatian: Žene koje su se javile dobrovoljno i primale više uzastopnih doza izravno na cerviks i vaginu u količini koja je odgovarala do peterostrukoj preporučenoj dozi za muškog partnera imale su najveće zabilježene razine lidokaina u plazmi manje od 8 % toksične razine, dok su razine prilokaina u plazmi bile manje od 1 % toksične razine.
English: How to store Senstend
Croatian: Kako primjenjivati Senstend
English: In a carcinogenicity study of rats exposed to 2,6-xylidine in utero, postnatally and throughout their lifetime, tumours in the nasal cavity, subcutaneous tumours and liver tumours were observed.
Croatian: U studiji kancerogenosti na štakorima izloženim 2,6-ksilidinu in utero, postnatalno i tijekom života, primijećeni su tumori u nosnoj šupljini, potkožni tumori i tumori jetre.
English: Prilocaine is reported to be 55% bound to plasma proteins, including alpha-1-acid glycoprotein.
Croatian: Zabilježeno je da je 55 % prilokaina vezano na proteine plazme, uključujući alfa-1 kiseli glikoprotein.
English: In Senstend-treated subjects, IELT and IPE scores increased at the first measured timepoint.
Croatian: U ispitanika liječenih lijekom Senstend, IELT i IPE rezultati povećali su se pri prvom mjerenju.
English: Clinical trials have shown Senstend to increase the intra-vaginal ejaculatory latency time (IELT), increase control over ejaculation and reduce the feelings of distress in patients with premature ejaculation as measured by the Index of Premature Ejaculation (IPE).
Croatian: Klinička su ispitivanja pokazala da Senstend povećava trajanje vremena intravaginalne latencije ejakulacije (engl. intra-vaginal ejaculatory latency time - IELT), povećava kontrolu nad ejakulacijom i smanjuje osjećaj tjeskobe u pacijenata s preuranjenom ejakulacijom mjereno indeksom preuranjenje ejakulacije (engl.
English: Senstend is only indicated for application to the glans penis.
Croatian: Senstend je indiciran samo za primjenu na glaviću penisa.
English: The lidocaine metabolite 2,6-xylidine has genotoxic potential in vitro.
Croatian: Metabolit lidokaina 2,6-ksilidin ima genotoksični potencijal in vitro.
English: EXP Discard 12 weeks after first use.
Croatian: Baciti 12 tjedana nakon prve uporabe.
English: • pain in the vagina
Croatian: • bol u vagini
English: Prilocaine was not genotoxic and the carcinogenic potential of prilocaine has not been studied.
Croatian: Prilokain nije bio genotoksičan, a njegov karcinogeni potencijal nije ispitan.
English: As a precautionary measure, it is preferable to avoid the use of Senstend during pregnancy unless effective male barrier contraceptive measures are taken in order to avoid potential foetal exposure.
Croatian: Kao mjeru opreza preporučuje se izbjegavati primjenu lijeka Senstend za vrijeme trudnoće, osim ako se ne upotrijebi mehanička metoda muške kontracepcije kako bi se spriječilo potencijalno izlaganje ploda.
English: Adverse drug reactions in male glans-penis-treated subjects System Organ Class
Croatian: Nuspojave u muškaraca liječenih primjenom na glavić penisa Klasa organskog sustava